| Strategy | Number of patients fulfilling each strategy (n = 1222) (%) | Number of patients with mutations in MLH1 or MSH2 (n = 8) (%) | Number of patients with mutations missed by each strategy (n = 8) (%) |
| Amsterdam II | 22 (2) | 4 (50) | 4 (50) |
| Any RBG | 287 (23) | 8 (100) | 0 |
| Universal MMR deficiency testing* | 91 (7) | 8 (100) | 0 |
| PREMM ⩾5% | 396 (32) | 8 (100) | 0 |
| PREMM ⩾10% | 130 (11) | 6 (75) | 2 (25) |
| PREMM ⩾20% | 32 (3) | 5 (62) | 3 (37) |
| PREMM ⩾40% | 9 (<1) | 2 (25) | 6 (75) |
| Barnetson ⩾0.5% | 349 (29) | 7 (87) | 1 (0.1) |
| Barnetson ⩾5% | 77 (6) | 6 (75) | 2 (25) |
| Barnetson ⩾20% | 29 (2) | 4 (50) | 4 (50) |
| Barnetson ⩾45% | 14 (1) | 3 (37) | 5 (62) |
RBG, revised Bethesda guidelines; MMR, mismatch repair.
*Considered as high microsatellite instability (MSI) or loss of protein expression by immunohistochemistry (IHC).